|1.||Bielekova, Bibiana: 11 articles (05/2015 - 06/2004)|
|2.||Waldmann, Thomas A: 11 articles (12/2014 - 11/2003)|
|3.||Martin, Roland: 7 articles (12/2014 - 06/2004)|
|4.||Elkins, Jacob: 6 articles (10/2015 - 04/2010)|
|5.||Nussenblatt, Robert B: 6 articles (11/2009 - 11/2003)|
|6.||Foster, C Stephen: 6 articles (05/2009 - 10/2004)|
|7.||Havrdova, Eva: 5 articles (10/2015 - 06/2013)|
|8.||Riester, Katherine: 4 articles (10/2015 - 12/2011)|
|9.||O'Neill, Gilmore: 4 articles (10/2015 - 04/2010)|
|10.||Giovannoni, Gavin: 4 articles (05/2014 - 06/2013)|
02/01/2008 - "Daclizumab therapy was effective in stabilizing vision and decreasing inflammation in most patients with BSCR. "
01/01/2014 - "The inflammation observed in the anterior chamber of the eyes when Daclizumab was administered with endotoxin was largely prevented since the aqueous humor protein concentration substantially lowered concomitantly with a significant reduction in the uveal and vitreous histopathological grading. "
04/01/2001 - "When Daclizumab treatment was started well after immunization but before the expected onset of CIA a significant reduction of joint-inflammation and joint-erosion was observed. "
05/01/2009 - "Daclizumab is effective in controlling inflammation in patients with stubborn non-infectious ocular inflammation. "
10/01/2007 - "Four of 10 eyes (40%) in the daclizumab group demonstrated an improvement in vision with eight of 10 eyes (80%) demonstrating an improvement in inflammation. "
05/01/2004 - "The adverse-event profiles were comparable among the three groups, except for a higher incidence of infection and readmissions in group III. Daclizumab was safe and effective in reducing the incidence of acute rejection when compared to no induction. "
01/01/2001 - "Clinical experience from trials to date indicate that daclizumab has a tolerability profile similar to placebo with no significant effect on the incidence of infection. "
07/27/1999 - "In the triple therapy study there was no evidence of any difference in CMV rate or course of disease between the two treatment arms, although in the dual therapy study a decrease in the incidence of CMV infection was observed in the patients treated with daclizumab. "
01/01/2014 - "However, several potentially serious and newly emerging AEs (mainly infections, skin reactions, elevated liver function tests and autoimmune phenomena in several body organs) may require strict safety monitoring programs in future clinical practice and place daclizumab together with other new and highly effective MS drugs as a second-line therapy. "
09/01/2012 - "Daclizumab was well tolerated, but infections were common. "
02/01/2005 - "Long-term humanized anti-interleukin-2 (IL-2) receptor alpha (Daclizumab) therapy has few side effects and is as effective as standard immunosuppression for treating severe uveitis. "
12/01/2004 - "Daclizumab is effective and safe for long-term use in the treatment of uveitis which cannot be kept under control by other treatments. "
06/22/1999 - "To evaluate the safety and potential therapeutic activity of humanized anti-IL-2 receptor mAb (Daclizumab) therapy in the treatment of patients with severe, sight-threatening, intermediate and posterior noninfectious uveitis, a nonrandomized, open-label, pilot study was performed. "
09/01/2008 - "Following promising observations in uveitis, daclizumab has since been tested in a number of small clinical trials in MS based on the rationale that blocking CD25 would prevent the expansion of autoreactive T-lymphocytes. "
11/01/2003 - "These studies provide preliminary evidence that regularly administered long-term daclizumab therapy can be given in lieu of standard immunosuppression for years to treat severe uveitis and that subcutaneously administered daclizumab appeared to be a clinically viable treatment strategy. "
|4.||Graft vs Host Disease (Graft-Versus-Host Disease)
11/01/2006 - "In a phase II study, daclizumab was given as single second-line agent to 62 patients with steroid-refractory acute graft-versus-host disease (aGVHD). "
05/01/2009 - "Daclizumab therapy for children with corticosteroid-resistant acute graft-vs.-host disease."
09/01/2007 - "Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease."
11/01/2006 - "Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease."
01/01/2006 - "Daclizumab for children with corticosteroid refractory graft-versus-host disease."
|5.||Relapsing-Remitting Multiple Sclerosis
06/22/2013 - "We assessed whether daclizumab high-yield process (HYP) would be effective when given as monotherapy for a 1 year treatment period in patients with relapsing-remitting multiple sclerosis. "
01/01/2012 - "The anti-CD25 treatment of daclizumab appears to be effective in patients with relapsing remitting multiple sclerosis (RRMS) as regards clinical and MRI outcomes. "
01/01/2010 - "The anti-CD25 treatment of daclizumab appears to be effective in patients with relapsing remitting multiple sclerosis (RRMS) as regards clinical and MRI outcomes. "
01/01/2015 - "In this study, we investigated the effect of daclizumab-mediated CD25 blockade on Treg homeostasis in patients with relapsing-remitting multiple sclerosis. "
05/01/2014 - "Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial."
|3.||Interleukin-2 Receptors (IL 2 Receptor)
|5.||TNFR-Fc fusion protein (etanercept)
|7.||Immunosuppressive Agents (Immunosuppressants)
|1.||Transplantation (Transplant Recipients)
|5.||Homologous Transplantation (Allograft)